The Medroxyprogesterone Acetate Market To Witness Electronic Prescribing

A synthetic version of progesterone, 17α-hydroxy-6α-methylprogesterone acetate, is also known as medroxyprogesterone acetate. Medroxyprogesterone acetate is a more potent derivative of medroxyprogesterone, which is usually injected. Medroxyprogesterone acetate, given every 3 months, prevents ovulation and follicle maturation during endometrial thinning and provides a contraceptive effect.

The Medroxyprogesterone acetate market is being driven by a growing need for contraceptive measures and government initiatives to raise awareness related to various contraceptive methods. There are various predictive initiatives taken to understand the demand for medroxyprogesterone depoacetate (DMPA) as a contraceptive measure. In January 2015, the Concept Foundation signed with the William Davidson Institute (WDI) to understand the demand for DMPA in low- and middle-income countries.

Manufacturers are currently trying to develop low-dose injections of medroxyprogesterone acetate via the subcutaneous route to reduce some of the side effects associated with weight gain and metabolic effects.

Get a sample copy of this report @ https://www.persistencemarketresearch.com/samples/15688

Based on end use

• Contraceptive
• Hormone replacement therapy
• Treatment of endometriosis
• other

Based on the route of administration

• Oral
• Parenteral

Sayana Press was approved by UK authorities in 2015 for a three-month progestin-only injectable contraceptive. PATH is working with the Ministry of Health in Uganda and Senegal to study Sayana Press self-injection and how it works for women.

Through the PATH initiative since 2014, this contraceptive is available in remote areas of Uganda, Senegal, Niger and Burkina Faso. Sayana Press is regulatory approved in Europe and 25 other countries. In 2014, Children’s Investment Fund Foundation (CIFF), Bill & Melinda Gates Foundation, and Pfizer Inc. decided to offer Sanaya Press to buyers from 69 countries for US $ 1 each.

Request a table of contents here for a complete list of market players @  https://www.persistencemarketresearch.com/toc/15688

Public and private partners announced at the London Summit that they will reach the poorest country in about 12 million Sayana Presses by 2020. Injctables has always been a popular contraceptive method in sub-Saharan Africa, so the presentation by Sayana Press inj is expected to increase the demand for Uniject devices. The all-in-one pre-file injection system enhances safety and enhances access through non-clinical channels.

In terms of geography, the Medroxyprogesterone acetate market is divided into five regions, including North America, Asia Pacific, Middle East & Africa, Latin America and Europe. Due to the presence of major market players, technological advances, and research investments, North America has become the dominant region of the cardiac biomarker market. In addition, there are many start-ups seeking to enter the new technology and more effective medroxyprogesterone acetate market.

Book Now for Exclusive Analyst Support @ https://www.persistencemarketresearch.com/checkout/15688

Developing countries are focusing on reducing facts and maternal mortality by legalizing the use of injectable contraceptives. One such initiative was taken by Haryana, the first state in the country to implement the use of injectable contraceptives. The project will begin in nine blocks in the state and will make injections available free of charge at all district hospitals, primary health centers, and community health centers.

Participants in the Medroxyprogesterone acetate market include Pfizer, Phanton Pharma, Gador SA, Sigma-Aldrich, Teva Pharmaceutical Industries, Greenstone LLC, Serum International, West Coast Pharmaceuticals, and Arrow. .. Pharma Group, and Zuche Pharmaceuticals Pvt. Ltd.

About Us :-